

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BIGHAM, Eric Cleveland et al.

JC13 Res'd PCT/PTO 23 OCT 2001

International Application No.: PCT/EP00/03848

Group Art Unit:

International Filing Date: 28 APRIL 2000

Examiner:

For: IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

Box PCT/EO/DO/US, Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- Copies of the references are enclosed.
 - Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
 - A copy of the International Search Report which issued on International Application No. PCT/EP00/03848 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.
- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
 - Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. _____

In accordance with the requirements of 37 CFR 1.97(d):

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge any required fees to Deposit Account No. 07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert H. Brink
Attorney of Record
Registration No. 36,094

Dated: 22 October 2001
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-3323
Facsimile: (919) 483-7988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ATTORNEY-CLIENT MARK OFFICE

JC13 Rec'd PCT/PTO 23 OCT 2001

Applicant: BIGHAM, Eric Cleveland et al.

Group Art Unit:

International Application No.: PCT/EP00/03848

Examiner:

International Filing Date: 28 APRIL 2000

For: IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

Box PCT/EO/DO/US, Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- Copies of the references are enclosed.
 Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. PCT/EP00/03848 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
 Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

10/01/9976

JPO Rec'd PCT/PTO 23 OCT 2001

Docket No. PU3650USw


In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge any required fees to Deposit Account No. 07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert H. Brink
Attorney of Record
Registration No. 36,094

Dated: 22 October 2001
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-3323
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU3650USw	INT'L APPLICATION NO. PCT/EP00/03848		
				APPLICANT BIGHAM et al.			
				INT'L FILING DATE 28 April 2000			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	3,754,002	Aug 21, 1973	Brown et al.			
	AB	4,506,074	Mar 19, 1985	Huff et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	BA	EP 0 887 346	30 Dec 1998	PCT			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	CA	Saari, Walfred S., J. Med. Chem., (1983), 26, 1769-72					
Continue on page _____							
EXAMINER					DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXPRESS MAIL LABEL
NO. E13959 '3218US